BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385]
URL: https://www.wjgnet.com/1948-5182/full/v8/i8/385.htm
Number Citing Articles
1
Jie Wang, Junqiao Jia, Ran Chen, Shanlong Ding, Qiang Xu, Ting Zhang, Xiangmei Chen, Shuang Liu, Fengmin Lu. RFX1 participates in doxorubicin‐induced hepatitis B virus reactivationCancer Medicine 2018; 7(5): 2021 doi: 10.1002/cam4.1468
2
Tsofia Inbar, Shehrban Sobeh Khalil, Ron Ram, Chezi Ganzel, Yishai Ofran. Low risk for viral reactivation during induction for acute myeloid leukemia in patients with resolved hepatitis B infectionLeukemia & Lymphoma 2020; 61(5): 1260 doi: 10.1080/10428194.2019.1702187
3
Alexandr Zinchuk, Oleksandr Herasun, Andrij Zadorozhnyi, Olga Vorozhbyt, Borys Gerasun. INFLUENCE OF AUTOLEUKOCYTE VACCINATION ON ACTIVITY LEVEL OF TUMOR NECROSIS FACTOR ALPHA IN PATIENTS WITH CHRONIC HEPATITIS BWiadomości Lekarskie 2019; 72(1): 31 doi: 10.36740/WLek201901106
4
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani. Liver Illness and Psoriatic PatientsBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/3140983
5
Jason T. Blackard, Kenneth E. Sherman. Hepatitis B virus (HBV) reactivation—The potential role of direct‐acting agents for hepatitis C virus (HCV)Reviews in Medical Virology 2018; 28(4) doi: 10.1002/rmv.1984
6
Yu-tuan Wu, Xin Li, Zi-li Liu, Zhou Xu, Wei Dai, Ke Zhang, Jiu-song Wu, Bilal Arshad, Kai-nan Wu, Ling-quan Kong, Chiaho Shih. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysisPLOS ONE 2017; 12(6): e0179680 doi: 10.1371/journal.pone.0179680
7
Ioanna Aggeletopoulou, Christos Konstantakis, Spilios Manolakopoulos, Christos Triantos. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis CWorld Journal of Gastroenterology 2017; 23(24): 4317-4323 doi: 10.3748/wjg.v23.i24.4317
8
Eileen L. Yoon, Hyung Joon Yim. Updated Treatment of Chronic Hepatitis BThe Korean Journal of Medicine 2019; 94(3): 252 doi: 10.3904/kjm.2019.94.3.252
9
Maria Guarino, Marco Picardi, Anna Vitiello, Novella Pugliese, Matilde Rea, Valentina Cossiga, Fabrizio Pane, Nicola Caporaso, Filomena Morisco. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for LymphomaAnnals of Hepatology 2017; 16(2): 198 doi: 10.5604/16652681.1231579
10
Jacinta A. Holmes, Ming-Lung Yu, Raymond T. Chung. Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individualsExpert Opinion on Drug Safety 2017; 16(6): 651 doi: 10.1080/14740338.2017.1325869
11
Romina Salpini, Arianna Battisti, Luna Colagrossi, Domenico Di Carlo, Lavinia Fabeni, Lorenzo Piermatteo, Carlotta Cerva, Miriam Lichtner, Claudio Mastroianni, Massimo Marignani, Sarah Maylin, Constance Delaugerre, Filomena Morisco, Nicola Coppola, Aldo Marrone, Mario Angelico, Loredana Sarmati, Massimo Andreoni, Carlo‐Federico Perno, Francesca Ceccherini‐Silberstein, Valentina Svicher. A snapshot of virological presentation and outcome of immunosuppression‐driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infectionJournal of Viral Hepatitis 2019; 26(7): 846 doi: 10.1111/jvh.13101
12
Rafael Mican, Carmen Busca Arenzana, Julia Vasquez, German Daroca, Ignacio Perez-Valero, Luz Martin-Carbonero. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological statusAIDS 2021; 35(10): 1707 doi: 10.1097/QAD.0000000000002941
13
Takako Inoue, Takeshi Matsui, Yasuhito Tanaka. Novel strategies for the early diagnosis of hepatitis B virus reactivationHepatology Research 2021; 51(10): 1033 doi: 10.1111/hepr.13699
14
Shih-Yu Yang, Tsung-Hui Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Ming-Chao Tsai, Kuo-Chin Chang, Yi-Hao Yen, Po-Lin Tseng. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessationJournal of Infection and Public Health 2023; 16(11): 1852 doi: 10.1016/j.jiph.2023.08.006
15
Anil Arora, Anil C. Anand, Ashish Kumar, Shivaram P. Singh, Rakesh Aggarwal, Radha K. Dhiman, Shyam Aggarwal, Seema Alam, Pradeep Bhaumik, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Ashok Kumar, Manoj Kumar, Kaushal Madan, Natarajan Murugan, Aabha Nagral, Amarender S. Puri, Padaki N. Rao, Neeraj Saraf, Vivek A. Saraswat, Sanjeev Sehgal, Praveen Sharma, Koticherry T. Shenoy, Manav Wadhawan. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or CorticosteroidsJournal of Clinical and Experimental Hepatology 2018; 8(4): 403 doi: 10.1016/j.jceh.2018.06.010
16
Martina Vitrone, Domenico Iossa, Luca Rinaldi, Pia Clara Pafundi, Rosa Molaro, Antonio Parrella, Roberto Andini, Enrico Ragone, Ciro Maiello, Rosa Zampino, Emanuele Durante-Mangoni. Hepatitis B virus reactivation after heart transplant: Incidence and clinical impactJournal of Clinical Virology 2017; 96: 54 doi: 10.1016/j.jcv.2017.09.011
17
Yu-Hung Wang, Ja-Der Liang, Wang-Huei Sheng, Feng-Ming Tien, Chien-Yuan Chen, Hwei-Fang Tien. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemiaLeukemia Research 2019; 81: 95 doi: 10.1016/j.leukres.2019.05.001
18
Hyun Jae Kim, Seonkyung Lee, Yu Jin Koo, Eunjin Kwon, Hyo-Jung Kim, Jeong-Yoon Choi, Ji-Soo Kim. Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory PseudotumorsJournal of Clinical Neurology 2020; 16(4): 674 doi: 10.3988/jcn.2020.16.4.674
19
Lan-Ying He, Yu-Lan Wang, Xu Tian, Wei-Qing Chen. The association of hepatitis B virus screening and antiviral prophylaxis with adverse liver outcomes in Chinese cancer patients undergoing chemotherapyMedicine 2020; 99(14): e19647 doi: 10.1097/MD.0000000000019647
20
Catarina Meng, Carolina Belino, Luciano Pereira, Ana Pinho, Susana Sampaio, Isabel Tavares, Manuela Bustorff, António Sarmento, Manuel Pestana. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experienceNefrología (English Edition) 2018; 38(5): 545 doi: 10.1016/j.nefroe.2018.02.013
21
Eimear Kitt, Molly Hayes, Ana María Cárdenas, Abby M. Green. Interpretation and management of positive anti‐hepatitis B core antibody tests in immunocompromised pediatric patientsTransplant Infectious Disease 2019; 21(3) doi: 10.1111/tid.13074
22
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal DiseasesIntestinal Research 2020; 18(1): 18 doi: 10.5217/ir.2019.09155
23
Wei Huang, Lingyao Du, Hong Tang. Hepatitis B virus reactivation: overview and managementFuture Virology 2021; 16(12): 821 doi: 10.2217/fvl-2021-0275
24
UEG Week 2018 Poster PresentationsUnited European Gastroenterology Journal 2018; 6(S8) doi: 10.1177/2050640618792819
25
Matthew Kelling, Lubomir Sokol, Samir Dalia. Hepatitis B Reactivation in the Treatment of Non-Hodgkin LymphomaCancer Control 2018; 25(1): 107327481876787 doi: 10.1177/1073274818767879
26
Catarina Meng, Carolina Belino, Luciano Pereira, Ana Pinho, Susana Sampaio, Isabel Tavares, Manuela Bustorff, António Sarmento, Manuel Pestana. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experienceNefrología 2018; 38(5): 545 doi: 10.1016/j.nefro.2018.02.004
27
Kyo Izumida, Atsushi Kaneko, Kazuya Takahashi, Shigeru Kusumoto, Tomoko Narita, Akiyoshi Takami, Shinsuke Iida, Katsumi Aoyagi, Yasuhito Tanaka. Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzerHepatology Research 2018; 48(13): 1081 doi: 10.1111/hepr.13229
28
Martin Feuchtenberger, Arne Schäfer, Axel Philipp Nigg, Michael Rupert Kraus. Hepatitis B Serology in Patients with Rheumatic DiseasesThe Open Rheumatology Journal 2016; 10(1): 39 doi: 10.2174/1874312901610010039
29
Apostolos Koffas, Grace E Dolman, Patrick TF Kennedy. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for cliniciansClinical Medicine 2018; 18(3): 212 doi: 10.7861/clinmedicine.18-3-212
30
Rashed Abdelaal, Beshoy Yanny, Mohamed El Kabany. HBV/HCV Coinfection in the Era of HCV-DAAsClinics in Liver Disease 2019; 23(3): 463 doi: 10.1016/j.cld.2019.04.003
31
Stefano Piaserico, Francesco Messina, Francesco Paolo Russo. Managing Psoriasis in Patients with HBV or HCV Infection: Practical ConsiderationsAmerican Journal of Clinical Dermatology 2019; 20(6): 829 doi: 10.1007/s40257-019-00457-3
32
Hidetaka Matsuda, Katsushi Hiramatsu, Yu Akazawa, Takuto Nosaka, Yasushi Saito, Yoshihiko Ozaki, Ryoko Hayama, Kazuto Takahashi, Tatsushi Naito, Kazuya Ofuji, Masahiro Ohtani, Tomoyuki Nemoto, Yukio Hida, Hideki Kimura, Yoshihiro Soya, Yasunari Nakamoto. Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agentsJournal of Medical Virology 2018; 90(4): 712 doi: 10.1002/jmv.25011
33
J. Steuart Richards, Sharon Dowell, Mercedes Quinones. Comorbidity in Rheumatic Diseases2017; : 345 doi: 10.1007/978-3-319-59963-2_17
34
Aida Siyahian, Saad Ullah Malik, Adeela Mushtaq, Carol L. Howe, Aneela Majeed, Tirdad Zangeneh, Samar Iftikhar, Shahid Habib, Umar Zahid, Irbaz Bin Riaz, Zabih Warraich, Warda Faridi, Faiz Anwer. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-AnalysisBiology of Blood and Marrow Transplantation 2018; 24(7): 1483 doi: 10.1016/j.bbmt.2018.02.027
35
Davide Fiore Bavaro, Deborah Fiordelisi, Gioacchino Angarano, Laura Monno, Annalisa Saracino. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infectionsExpert Opinion on Drug Safety 2020; 19(7): 817 doi: 10.1080/14740338.2020.1767585
36
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung, Man Fai Law. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy eraWorld Journal of Gastroenterology 2023; 29(33): 4942-4961 doi: 10.3748/wjg.v29.i33.4942
37
Xing Cao, Yafei Wang, Panyun Li, Wei Huang, Xiaojuan Lu, Hongda Lu. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management StrategiesFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.685706
38
Yuqin Song, Hervé Tilly, Shinya Rai, Huilai Zhang, Jie Jin, Hideki Goto, Yasuhito Terui, Ho-Jin Shin, Won Seog Kim, Junning Cao, Jifeng Feng, Hyeon Seok Eom, Tae Min Kim, Xavier Cheng-Hong Tsai, Jyh-Pyng Gau, Hideo Koh, Liling Zhang, Yongping Song, Yu Yang, Wei Li, He Huang, Kiyoshi Ando, Jeff P. Sharman, Laurie H. Sehn, Lilian Bu, Xin Wang, Yanwen Jiang, Jamie Hirata, Calvin Lee, Jun Zhu, Koji Izutsu. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialBlood 2023; 141(16): 1971 doi: 10.1182/blood.2022017734
39
Marius Rademaker, Karen Agnew, Nicholas Anagnostou, Megan Andrews, Katherine Armour, Christopher Baker, Peter Foley, Kurt Gebauer, Monisha Gupta, Gillian Marshman, Diana Rubel, John Sullivan, Li‐Chuen Wong. Psoriasis and infection. A clinical practice narrativeAustralasian Journal of Dermatology 2019; 60(2): 91 doi: 10.1111/ajd.12895
40
KASL clinical practice guidelines for management of chronic hepatitis BClinical and Molecular Hepatology 2019; 25(2): 93 doi: 10.3350/cmh.2019.1002
41
Alberto Enrico Maraolo, Ivan Gentile, Antonio Riccardo Buonomo, Biagio Pinchera, Guglielmo Borgia. Current evidence on the management of hepatitis B in pregnancyWorld Journal of Hepatology 2018; 10(9): 585-594 doi: 10.4254/wjh.v10.i9.585
42
Yachao Tao, Dongbo Wu, Lingyun Zhou, Enqiang Chen, Changhai Liu, Xiaoqiong Tang, Wei Jiang, Ning Han, Hong Li, Hong Tang. Hepatitis B Virus InfectionAdvances in Experimental Medicine and Biology 2020; 1179: 137 doi: 10.1007/978-981-13-9151-4_6
43
María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban, Vincent Wong. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin studyPLOS ONE 2017; 12(9): e0184550 doi: 10.1371/journal.pone.0184550
44
Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapyBlood 2019; 133(2): 137 doi: 10.1182/blood-2018-04-848044
45
G. Tapia Rico, M.M. Chan, K.F. Loo. The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidenceCancer Treatment Reviews 2020; 86: 102011 doi: 10.1016/j.ctrv.2020.102011
46
Reem A. Shalabi, Michelle A. Worst, Thomas E. Hughes, Tracey Walsh‐Chocolaad, Lisa Cook, Kristen Gunn, Brian Wells, Rodica Ciurea, Georg Aue, Xin Tian, Richard W. Childs. Haematopoietic stem cell transplant patients have a high initial failure rate to hepatitis B vaccination that can be overcome with subsequent vaccination seriesBritish Journal of Haematology 2022; 196(6): 1404 doi: 10.1111/bjh.17991
47
A. Marrone, N. Capoluongo, C. D'Amore, M. Pisaturo, M. Esposito, S. Guastafierro, I. Siniscalchi, M. Macera, A. Boemio, L. Onorato, L. Rinaldi, C. Minichini, L. E. Adinolfi, E. Sagnelli, L. Mastrullo, N. Coppola. Eighteen‐month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapyJournal of Viral Hepatitis 2018; 25(2): 198 doi: 10.1111/jvh.12802
48
Ahmad AlEnizi, Khaled AlSaeid, Adel Alawadhi, Eiman Hasan, Entesar H. Husain, Ahmad AlFadhli, Aqeel Ghanem, Fatemah Abutiban, Yaser Ali, Adeeba Al-Herz, Khuloud Mohammed, Waleed Alkandari, Ali Aldei, Hebah Alhajeri, Ahmad Dehrab, Sawsan Hayat. Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic DiseasesInternational Journal of Rheumatology 2018; 2018: 1 doi: 10.1155/2018/5217461
49
KASL clinical practice guidelines for management of chronic hepatitis BClinical and Molecular Hepatology 2022; 28(2): 276 doi: 10.3350/cmh.2022.0084
50
Beshoy T. Yanny, Nyan L. Latt, Sammy Saab, Steven Han, Gina Choi, Jason Kramer, Amandeep K. Sahota. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus InfectionJournal of Clinical Gastroenterology 2018; 52(10): 908 doi: 10.1097/MCG.0000000000000986